Advanced Computing in the Age of AI | Thursday, March 28, 2024

Stratipath Wins Innovation Prize for Advances in AI-based Precision Oncology 

STOCKHOLM, Oct. 25, 2022 -- AI-precision oncology pioneers Stratipath has been awarded the Athena Prize, one of Sweden’s most prestigious awards for innovation in health care for the development of their AI-based solution for improved prognostic analysis of breast cancer, using only microscopy images. The jury praised the company’s ‘impressive achievement’ in taking basic academic research through to the first approval for clinical use earlier this year. The tool will provide significant benefits for healthcare systems and individual patients by enabling cost-effective and equivalent precision medical diagnostics.

The company was also listed in tech magazine Ny Teknik’s 33-list, which selects the most promising Swedish start-ups each year.

”We are very proud of our solution and what we have achieved so far. On top of getting public recognition through the Athena Prize, we are also delighted to be receiving fantastic feedback from our customers who are excited at the prospects of its clinical roll-out,” said Fredrik Wetterhall, CEO of Stratipath.

Following receipt of its CE-IVD mark in May, the company expects its solution, ”Stratipath Breast” to be in clinical use in Swedish hospitals within months. By using deep learning to analyze tissue samples from biopsies or resected tumors, Straipath can assess the risk of recurrence. The company, founded in 2019 and based on many years of research carried out at the Karolinska Institutet, hopes to provide more patients with access to precision medicine than is currently possible and thereby create the conditions for more equal cancer care.

Stratipath Breast will provide improved stratification for approximately 50% of all breast cancer patients whose current diagnoses are in a ‘grey area’, and provide little information on the aggressiveness of their cancer. This autumn several Swedish regions are implementing the Stratipath Breast precision oncology approach, and in 2023 it will be launched more widely in Sweden and on the European market.

Using deep learning, Stratipath Breast enables intermediate risk tumors to be classified into low- and high-risk groups, based on grade-related tumor morphology. The stratification comes from a rigorous scientific development process and validation using multi-source real-world datasets, comprising histopathology images and associated clinical outcome data.

The system measures risk-associated morphological patterns locally in the image and aggregates this information across the analyzed tissue area to establish whether the tumor belongs to the high- or low-risk group. Results from Stratipath Breast provide prognostic information and are intended to be used as a decision-support tool, together with other clinical and pathological information.

Stratipath Breast provides an optimal workflow through integration with leading digital pathology solutions. It can also be used on its own, via the Stratipath customer web portal. Access to Stratipath Breast will be provided as a Software as a Service solution, by a subscription or pay-as-you-use model. It is currently not marketed in the USA.

The Swedish Athena Prize

The Swedish Athena Prize is awarded by the Swedish Research Council, Forte, Swedish Medtech, Sweden’s Municipalities and Regions, Vinnova (the Swedish innovation agency) and the publisher Dagens Medicin (Daily medicine) together with Sweden’s pharmaceutical industry trade association LIF.

The 33-list

The 33-list by the Swedish tech magazine Ny Teknik acknowledges Sweden’s 33 best and most promising technology startup companies with the potential to reach an international market. Altogether Ny Teknik has evaluated over 300 tech companies this year before presenting the 33 winners.

About Stratipath

Stratipath is a spin-out from Karolinska Institutet in Stockholm, Sweden, bringing pioneering research in AI and precision medicine into clinical use. The company was founded in 2019 by Johan Hartman, M.D., PhD, Mattias Rantalainen, PhD and Fredrik Wetterhall with a mission to radically improve cancer treatment decisions and patient outcomes. Stratipath offers an AI precision diagnostic solution for healthcare and can offer an accelerated path for pharma and biotech companies to identify patients most likely to benefit from novel therapies.


Source: Stratipath

..

EnterpriseAI